Selection of beneficiaries of immunotherapy for gastric cancer
WANG Gui-hua
ZHOU Ying-bin
Abstract：Currently,the identification of predictive biomarkers for gastric cancer is paramount in effectively screening individuals who would benefit from immunotherapy for this condition.The Programmed Death Receptor Ligand-1(PD-L1)expression score is a widely utilized clinical biomarker for assessing the effectiveness of immunotherapy in gastric cancer.However,there is still a need for further standardization of the measurement platform,assessment indicators,and cutoff values for PD-L1 expression levels.While microsatellite instability(MSI)status,tumor mutational burden(TMB)levels,and EB virus(EBV)infection have demonstrated promising predictive value in certain clinical trials of gastric cancer immunotherapy,extensive clinical studies are necessary for validation.Moreover,POLE/POLD1 mutations,Helicobacter pylori(Hp)infection,and liquid biopsy have introduced new avenues for investigating predictive biomarkers for gastric cancer immunotherapy.Currently,no precise standard exists for the screening of populations that would benefit from immunotherapy for gastric cancer.The joint utilization of multiple predictive indicators,including the PD-L1 expression score,may enhance the accuracy of screening.
Keywords：gastric cancerimmunotherapyimmune checkpoint inhibitorspredictive biomarker
Publication Date：2024-10-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 1138-1143 )